“Summary
Grunenthal GmbH (Grunenthal) is an international research-based pharmaceutical company. It holds expertise in the therapeutic area of pain. The company researches, develops, produces and markets a wide range of products for the treatment of pain and innovative formulations for established active substances.. Some of the company鈥檚 key products include Versatis, Zaldiar, Palexia, Transtec, Tramal, Norspan, Recivit and Tapentadol, among others. It also develops solutions for the improved management of chronic pain. Grunenthal is the research-oriented pharmaceutical company with major investments in research and development. It markets its products in more than 155 countries and operates through its affiliates in 25 countries. Grunenthal is headquartered in Aachen, Germany.
The company focuses on becoming the patient-centric company in the field of pain and be a leader in therapy innovation. It plans to increase its engagement and investments in the development of new products. In line with this the company entered into a commercial collaboration agreement with AcelRx Pharmaceuticals, Inc., for the European Union commercialization of AcelRx’s ZALVISO.
Grunenthal GmbH – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
– Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
– Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
– Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
– Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
– Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
– Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company鈥檚 (major public companies) key financial metrics and ratios.
– Business Description – A brief description of the company’s operations.
– Key Employees – A list of the key executives of the company.
– Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
– Key Competitors – A list of the key competitors of the company.
– Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
– The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
– The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
– Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company鈥檚 operations to identify potential customers and suppliers.
– The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
– Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
– Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.”
“Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 6
Grunenthal GmbH, Pharmaceuticals & Healthcare Deals By Type, 2009 to YTD 2015 7
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 8
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 9
Grunenthal GmbH, Medical Devices Deals, 2009 to YTD 2015 10
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2009 to YTD 2015 11
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Grunenthal Acquires Portfolio of Pharma Drugs from Biogen Labs 13
Grunenthal Acquires Pain Patent Portfolio From Nectid 14
Grunenthal Acquires Patent Portfolio From Protect Pharma 15
Partnerships 16
AcelRx Pharma Enters Into Commercialization Agreement With Grunenthal For Zalviso 16
Grunenthal Enters Into Agreement With Amura Therapeutics To Develop Protease Inhibitors For Pain and Inflammation 18
Xention Enters Into Co-Development Agreement With Grunenthal 19
Labopharm Enters Into Distribution Agreement With Grunenthal 20
Licensing Agreements 21
Grunenthal Terminates Licensing Agreement with Forest Labs Ireland for GRT 6005 and GRT 6006 21
Mundipharma Enters Into Licensing Agreement With Grunenthal 22
Grunenthal Enters Into Licensing Agreement With Purdue Pharma For IP Rights To Abuse-Deterrent Formulation Technology 23
Grunenthal Enters Into Licensing Agreement With Ethypharm For Fentanyl Sublingual Tablets 24
Grunenthal Enters Into Licensing Agreement With Horizon Pharma For Duexis 25
BioClinica Enters Into Licensing Agreement With Grunenthal For BioClinica OnPoint CTMS 26
Endo Pharma Terminates Licensing Agreement With Grunenthal For Axomadol 27
Forest Labs Terminates Its Licensing Agreement With Gruenenthal 28
Janssen Pharmaceutica Expands Licensing Agreement With Grunenthal 29
Endo Pharma Enters Into Licensing Agreement With Grunenthal 30
Asset Transactions 32
STADA Completes Acquisition Of Branded Product Portfolio In Central Europe From Grunenthal For US$230 Million 32
STADA Completes Acquisition Of Branded Product Portfolio In Eastern Europe And Middle East From Grunenthal For US$218 Million 34
Gedeon Richter Acquires Oral Contraceptive Portfolio From Grunenthal 36
Forest Labs Acquires Rights Of Colistin From Gruenenthal 37
Riemser Arzneimittel Acquires Anti-Infectives Product Portfolio Of Grunenthal 39
Acquisition 40
Grunenthal Acquires 81.59% Stake in Laboratorios Andromaco 40
Grunenthal Plans To Acquire Pain Therapeutics Company In Latin America 42
Grunenthal GmbH – Key Competitors 43
Key Employees 44
Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47″
“List of Tables
Grunenthal GmbH, Pharmaceuticals & Healthcare, Key Facts, 2013 1
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 6
Grunenthal GmbH, Pharmaceuticals & Healthcare Deals By Type, 2009 to YTD 2015 7
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 8
Grunenthal GmbH, Deals By Therapy Area, 2009 to YTD 2015 9
Grunenthal GmbH, Medical Devices Deals, 2009 to YTD 2015 10
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2009 to YTD 2015 11
Grunenthal Acquires Portfolio of Pharma Drugs from Biogen Labs 13
Grunenthal Acquires Pain Patent Portfolio From Nectid 14
Grunenthal Acquires Patent Portfolio From Protect Pharma 15
AcelRx Pharma Enters Into Commercialization Agreement With Grunenthal For Zalviso 16
Grunenthal Enters Into Agreement With Amura Therapeutics To Develop Protease Inhibitors For Pain and Inflammation 18
Xention Enters Into Co-Development Agreement With Grunenthal 19
Labopharm Enters Into Distribution Agreement With Grunenthal 20
Grunenthal Terminates Licensing Agreement with Forest Labs Ireland for GRT 6005 and GRT 6006 21
Mundipharma Enters Into Licensing Agreement With Grunenthal 22
Grunenthal Enters Into Licensing Agreement With Purdue Pharma For IP Rights To Abuse-Deterrent Formulation Technology 23
Grunenthal Enters Into Licensing Agreement With Ethypharm For Fentanyl Sublingual Tablets 24
Grunenthal Enters Into Licensing Agreement With Horizon Pharma For Duexis 25
BioClinica Enters Into Licensing Agreement With Grunenthal For BioClinica OnPoint CTMS 26
Endo Pharma Terminates Licensing Agreement With Grunenthal For Axomadol 27
Forest Labs Terminates Its Licensing Agreement With Gruenenthal 28
Janssen Pharmaceutica Expands Licensing Agreement With Grunenthal 29
Endo Pharma Enters Into Licensing Agreement With Grunenthal 30
STADA Completes Acquisition Of Branded Product Portfolio In Central Europe From Grunenthal For US$230 Million 32
STADA Completes Acquisition Of Branded Product Portfolio In Eastern Europe And Middle East From Grunenthal For US$218 Million 34
Gedeon Richter Acquires Oral Contraceptive Portfolio From Grunenthal 36
Forest Labs Acquires Rights Of Colistin From Gruenenthal 37
Riemser Arzneimittel Acquires Anti-Infectives Product Portfolio Of Grunenthal 39
Grunenthal Acquires 81.59% Stake in Laboratorios Andromaco 40
Grunenthal Plans To Acquire Pain Therapeutics Company In Latin America 42
Grunenthal GmbH, Key Competitors 43
Grunenthal GmbH, Key Employees 44
Grunenthal GmbH, Other Locations 45
Grunenthal GmbH, Subsidiaries 45″
“List of Figures
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 1
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 1
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 1
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 1
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 6
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 7
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 8
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 9
Grunenthal GmbH, Medical Devices Deals, 2009 to YTD 2015 10″